Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Etoposide

Antibodies

Antibodies, Monoclonal

Capecitabine

Paclitaxel

Carboplatin

Pemetrexed

Tislelizumab

Fluorouracil

Albumin-Bound Paclitaxel

Cisplatin

Oxaliplatin

Etoposide phosphate

Immunoglobulins

Tubulin Modulators

Antimitotic Agents

Antimetabolites

Immunosuppressive Agents

Immunologic Factors

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Antineoplastic Agents, Immunological

Folinic Acid

Folate

Vitamin B9

Cycle 1 (28 Days): A flat dose of ociperlimab as a single agent on Day 1. In the first cycle, 200 mg tislelizumab will be administered on Day 8.

If ociperlamib is tolerated in Cycle 1, participants will receive tislelizumab + ociperlimab sequentially on Day 29 and every 21 days for up to 8 months.

Participants with metastatic squamous NSCLC will receive ociperlamib + tislelizumab + paclitaxel/nab-paclitaxel + Carbo once every 3 weeks (Q3W) for 4 to 6 cycles (21 days each) followed by ociperlimab + tislelizumab Q3W)

Participants with metastatic squamous NSCLC will receive ociperlimab + tislelizumab + pemetrexed + Cis/Carbo Q3W for 4 to 6 cycles (21 days each) followed by ociperlamib+tislelizumab Q3W)

Participants with metastatic NSCLC (PD-L1 positive, \[TC\] ≥ 1%) will be treated with ociperlimab + tislelizumab

Patients with extensive stage SCLC will be treated with ociperlimab + tislelizumab + etoposide + Cis/Carbo Q3W for up to 6 to 8 cycles followed by ociperlamib+tislelizumab Q3W

Checkpoint inhibitor (CPI)-experienced NSCLC patients will be treated with ociperlimab plus tislelizumab

Patients with metastatic ESCC will be treated with ociperlimab + tislelizumab + cisplatin + 5-fluorouracil /paclitaxel Q3W for 6 cycles followed by ociperlamib+tislelizumab Q3W

Patients with metastatic EAC will be treated with ociperlimab + tislelizumab + cisplatin + 5-fluorouracil or paclitaxel Q3W for 6 cycles followed by ociperlamib+tislelizumab Q3W

Patients with recurrent or metastatic HNSCC (PD-L1 positive, vCPS≥ 1%) will be treated with ociperlimab + tislelizumab Q3W

Patients with metastatic G/GEJ carcinoma will be treated with ociperlimab + tislelizumab + \[oxalipatin + capecitabine\] or \[cisplatin + 5-fluorouracil\] Q3W for 6 cycles followed by ociperlamib+tislelizumab + capecitabine Q3W

Patients with metastatic NSCLC (PD-L1 positive, \[TC\] ≥ 1%) will be treated with tislelizumab in combination with ociperlimab 450mg, 900mg or 1800mg Q3W.

Administered as an intravenous (IV) injection

Ociperlimab

Administered in accordance with local guidelines, prescribing information/summary of product

Administered in accordance with local guidelines , prescribing information/summary of product

Nab paclitaxel

5fluorouracil

Study Director

The primary objectives of this study are : to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to determine the recommended Phase 2 dose (RP2D) of BGB-A1217 (known as Ociperlimab) in combination with tislelizumab in participants with advanced solid tumors in phase 1.

Primary objective of Phase 1b is to assess overall response rate (ORR) determined by Investigator per RECIST v1.1 for patients in each dose- expansion cohort

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Duration of response (DOR) will be determined from investigator derived tumor assessments per RECIST v. 1.1.

Disease control rate (DCR) will be determined from investigator derived tumor assessments per RECIST v. 1.1.

Progression free survival will be determined from investigator derived tumor assessments per RECIST 1.1.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors	NCT04047862	Locally Advance...	Ociperlimab Tislelizumab Pemetrexed Paclitaxel Nab paclitaxel Carboplatin Cisplatin Etoposide 5fluorouracil Oxaliplatin Capecitabine	18 Years -	BeiGene
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors	NCT04047862	Locally Advance...	Ociperlimab Tislelizumab Pemetrexed Paclitaxel Nab paclitaxel Carboplatin Cisplatin Etoposide 5fluorouracil Oxaliplatin Capecitabine	18 Years -	BeiGene

Spots Global Cancer Trial Database for locally advanced and metastatic solid tumors